Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) announces the successful completion of its acquisition of Elektrofi, Inc. (“Elektrofi”), a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon™. “Completing the acquisition of Elektrofi is a strategic milestone in our mission to expand Halozyme’s drug delivery technology offerings to biopharma companies. With the addition of the Hypercon ultra-high concentration microparticle formulation technology, we will be able to offer partners a diverse portfolio of drug delivery solutions,” said Dr. Helen Torley, President and Chief Executive of Halozyme.
Read the full article: Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery //
Source: https://www.prnewswire.com/news-releases/halozyme-completes-acquisition-of-elektrofi-expanding-breadth-of-offerings-in-drug-delivery-302618579.html